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ABSTRACT
Purpose: To evaluate the efficacy and safety of aripiprazole once-monthly 400 mg  
(AOM-400 mg), an extended-release injectable suspension of aripiprazole, in obese (body 
mass index [BMI], ≥30 kg/m2) and non-obese (BMI, <30 kg/m2) patients with schizophrenia.  
Methods: Data from a 38-week, double-blind, active-controlled noninferiority study 
(NCT00706654)1 with randomization (2:2:1) to AOM-400 mg, oral aripiprazole  
(10–30 mg/d), or aripiprazole once-monthly 50 mg (AOM-50 mg) assessing the efficacy 
and safety of aripiprazole in patients requiring chronic antipsychotic treatment were used 
for this post hoc analysis. We report the overall relapse rates in the 38-week randomized 
phase. Comparisons of overall relapse rates were analyzed using the chi-square test.
Results: 662 patients were randomized to AOM-400 mg (n=265), oral aripiprazole 
(n=266), or AOM-50 mg (n=131). Of these, the following were obese: AOM-400 mg,  
n=95 (36%); oral aripiprazole, n=95 (36%); and AOM-50 mg, n=43 (33%). In the obese 
patients, the overall relapse rate was significantly (P=0.0012) lower with AOM-400 mg 
(7.4%) than with AOM-50 mg (27.9%). The difference between AOM-400 mg and oral 
aripiprazole (8.4%) was not significant. In the non-obese patients, the overall relapse  
rate was significantly (P=0.0153) lower with AOM-400 mg (8.8%) than with AOM-50 mg  
(19.3%). The difference between AOM-400 mg and oral aripiprazole (7.6%) was not 
significant. For patients treated with AOM-400 mg, the most common treatment-emergent 
adverse events (AEs) (>10% in any group) for obese vs non-obese patients were insomnia 
(12.6% vs 11.2%, respectively), headache (12.6% vs 8.2%), injection site pain (11.6%  
vs 5.3%), akathisia (10.5% vs 10.6%), and upper respiratory tract infection (10.5% vs  
<5%). Increased weight was reported as an AE in 10.5% of obese and 8.2% of  
non-obese patients. In patients treated with 400 mg, the incidence of shifts from  
non-obese at baseline to obese during the randomized phase was 7.6% (n=13/170);  
the incidence of shifts from obese to non-obese was 17.9% (17/95).
Conclusions: The efficacy and tolerability of AOM-400 mg were similar in obese and 
non-obese subgroups.
INTRODUCTION
• There is growing evidence of the impact of pharmacologic agents on obesity.
• In some cases, dose adjustments are needed in obese patients (eg, they may require 
doses in the upper range of paliperidone palmitate).2 
• Aripiprazole once-monthly, a long-acting injectable solution of aripiprazole, is the first 
dopamine partial D2 agonist available as a long-acting injectable formulation.
• Because aripiprazole has less metabolic risk than other antipsychotics, it may be a 
suitable choice for patients already obese; therefore it is useful to know the efficacy  
and safety profile of aripiprazole once-monthly 400 mg in obese patients.
PURPOSE
• To evaluate efficacy and safety of aripiprazole once-monthly 400 mg, an 
extended-release injectable suspension of aripiprazole, in obese (body mass index 
[BMI] ≥30 kg/m2) and non-obese (BMI <30 kg/m2) patients with schizophrenia
METHODS
Patients
• Patients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revision) aged 18–60 years requiring chronic antipsychotic 
treatment were eligible.
Study Design
• This was a 38-week, randomized, double-blind, active-controlled study to assess the 
efficacy, safety, and tolerability of maintenance therapy with aripiprazole once-monthly 
400 mg for the treatment of schizophrenia (NCT00706654).
• A detailed study design has been reported previously.1
• Patients were randomized (2:2:1) to aripiprazole once-monthly 400 mg (initial dose  
of 400 mg with the option to reduce to 300 mg for tolerability), oral aripiprazole  
(10–30 mg/d), or a subtherapeutic dose of aripiprazole once-monthly (initial dose  
of 50 mg with the option to reduce to 25 mg). 
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Statistical Analysis
• Exploratory post hoc analyses were performed in subpopulations of obese  
(BMI ≥30 kg/m2) and non-obese (BMI <30 kg/m2) patients.
• The estimated relapse rate at week 26 and the overall relapse rate in the 38-week 
randomized phase were reported.
• Comparisons of estimated relapse rates at week 26 were analyzed using the z test 
based on Kaplan-Meier estimators and of the overall relapse rates over 38 weeks using 
the chi-square test.
• Tolerability was measured as common adverse events (≥10% in any treatment group).
RESULTS
• Treatment groups were comparable in the demographic profile and baseline 
characteristics (Table 1).
Table 1.  Baseline (Randomized Phase) Demographics and Characteristics in 
the Obese and Non-Obese Subpopulations
Aripiprazole Once-Monthly
400 mg
Oral Aripiprazole
10–30 mg/d
Aripiprazole Once-Monthly
50 mg
Obese
(n=95)
Non-Obese
(n=170)
Obese
(n=95)
Non-Obese
(n=171)
Obese
(n=43)
Non-Obese
(n=88)
Mean (SD) 
age, y 43.3 (9.5) 40.8 (10.8) 43.4 (10.7) 40.0 (10.8) 42.8 (8.8) 38.9 (9.8)
Men, n (%) 47 (49.5) 113 (66.5) 54 (56.8) 114 (66.7) 19 (44.2) 59 (67.0)
Race, n (%)
White 55 (57.9) 105 (61.8) 52 (54.7) 101 (59.1) 24 (55.8) 50 (56.8)
Black or 
African 
American
31 (32.6) 25 (14.7) 34 (35.8) 30 (17.5) 18 (41.9) 15 (17.0)
Asian 4 (3.2) 26 (15.3) 0 26 (15.2) 1 (2.3) 13 (14.8)
Other 6 (6.3) 14 (8.2) 8 (8.4) 14 (8.2) 0 10 (11.4)
Mean (SD) 
BMI, kg/m2 36.1 (5.7) 24.9 (2.9) 34.5 (4.8) 25.2 (3.0) 37.5 (7.7) 24.5 (3.2)
 BMI=body mass index.
• 70% of obese patients treated with aripiprazole once-monthly 400 mg completed the 
study compared with 77% in the non-obese group (Table 2).
• The most common reason for discontinuation among aripiprazole once-monthly  
400-mg treated patients was withdrawal of consent (Table 2).
Table 2.  Patient Disposition in the Randomized Phase in the Obese  
and Non-Obese Subpopulations
Aripiprazole Once-Monthly
400 mg
Oral Aripiprazole
10–30 mg/d
Aripiprazole Once-Monthly
50 mg
 
Patients, n (%)
Obese
(n=95)
Non-Obese
(n=170)
Obese
(n=95)
Non-Obese
(n=171)
Obese
(n=43)
Non-Obese
(n=88)
Completed 66 (69.5) 130 (76.5) 63 (66.3) 115 (67.3) 19 (44.2) 42 (47.7)
Discontinued 29 (30.5) 40 (23.5) 32 (33.7) 56 (32.7) 24 (55.8) 46 (52.3)
AEs 5 (5.3) 3 (1.8) 2 (2.1) 5 (2.9) 1 (2.3) 6 (6.8)
Impending 
relapse  
(with AE)
4 (4.2) 9 (5.3) 5 (5.3) 7 (4.1) 6 (14.0) 11 (12.5)
Withdrew 
consent 3 (3.2) 6 (3.5) 3 (3.2) 6 (3.5) 6 (14.0) 6 (6.8)
Impending 
relapse 
(without AE)
8 (8.4) 13 (7.6) 10 (10.5) 19 (11.1) 5 (11.6) 9 (10.2)
Lost to follow-up 2 (2.1) 2 (1.2) 2 (2.1) 8 (4.7) 3 (7.0) 3 (3.4)
Other 7 (7.4) 7 (4.1) 10 (10.5) 11 (6.4) 3 (7.0) 11 (12.5)
 AE=adverse event.
Relapse Rates/Exacerbation of Psychotic Symptoms
At Week 38
• In obese and non-obese patients
 – The overall relapse rate was statistically significantly lower with aripiprazole  
once-monthly 400 mg than with the subtherapeutic dose (Figure 1).
 – Aripiprazole once-monthly 400 mg and the oral formulation were not significantly 
different (Figure 1).
Figure 1. Overall Relapse Rates in the 38-Week Randomization Phase
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At Week 26
• In obese patients
 – The estimated relapse rate was significantly lower (P=0.035) with aripiprazole  
once-monthly 400 mg (6.54%) than with aripiprazole once-monthly 50 mg (30.24%). 
The difference between aripiprazole once-monthly 400 mg and oral aripiprazole 
(7.9%) was not significantly different.
• In non-obese patients
 – The estimated relapse rate was significantly lower (P=0.043) with aripiprazole  
once-monthly 400 mg (7.43%) than with aripiprazole once-monthly 50 mg (17.23%). 
The difference between aripiprazole once-monthly 400 mg and oral aripiprazole 
(7.65%) was not significantly different.
Safety and Tolerability
• The most common treatment-emergent adverse events (≥10% in either group) are 
reported in Table 3.
• Increased weight was reported as an adverse event in 10.5% of obese and 8.2% of 
non-obese patients receiving aripiprazole once-monthly 400 mg; a greater proportion of 
patients shifted from obese to non-obese than the reverse (Figure 2).
Table 3.  Treatment-Emergent Adverse Events (≥10% Incidence in Any 
Treatment Group) in Obese and Non-Obese Patients
Aripiprazole Once-Monthly
400 mg
Oral Aripiprazole
10–30 mg/d
Aripiprazole Once-Monthly
50 mg
 
Patients, n (%)
Obese
(n=95)
Non-Obese
(n=170)
Obese
(n=95)
Non-Obese
(n=171)
Obese
(n=43)
Non-Obese
(n=88)
Insomnia 12 (12.6) 19 (11.2) 13 (13.7) 24 (14.0) 5 (11.6) 13 (14.8)
Headache 12 (12.6) 14 (8.2) 14 (14.7) 16 (9.4) 2 (4.7) 5 (5.7)
Injection site pain 11 (11.6) 9 (5.3) 2 (2.1) 4 (2.3) 0 1 (1.1)
Akathisia 10 (10.5) 18 (10.6) 7 (7.4) 11 (6.4) 4 (9.3) 7 (8.0)
Upper respiratory 
tract infection 10 (10.5) <5% 5 (5.3) <5% 2 (4.7) <5%
Weight increase 10 (10.5) 14 (8.2) 17 (17.9) 18 (10.5) 2 (4.7) 5 (5.7)
Weight decrease 6 (6.3) 20 (11.8) 4 (4.2) 12 (7.0) 3 (7.0) 9 (10.2)
Back pain 5 (5.3) 5 (2.9) 9 (9.5) 5 (2.9) 8 (18.6) 7 (8.0)
Figure 2. Shifts in Obesity Status From Baseline to End of Study
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CONCLUSIONS
• The efficacy and tolerability of aripiprazole once-monthly 400 mg were 
similar in the obese and non-obese subgroups; thus dose adjustments 
are not necessary.
• The proportion of patients with shifts from obese to non-obese was 
numerically larger than of those shifting from non-obese to obese.
• Shifts from obese to non-obese are consistent with earlier data on 
the low-risk metabolic profile of aripiprazole tablets; nevertheless all 
patients taking antipsychotics should be monitored for weight and 
metabolic changes.
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